500,000 Shares in enGene Holdings Inc. (NASDAQ:ENGN) Bought by SR One Capital Management LP

SR One Capital Management LP acquired a new position in shares of enGene Holdings Inc. (NASDAQ:ENGN) in the second quarter, HoldingsChannel.com reports. The fund acquired 500,000 shares of the company’s stock, valued at approximately $4,715,000. enGene makes up about 1.5% of SR One Capital Management LP’s holdings, making the stock its 8th largest position.

Several other hedge funds also recently made changes to their positions in ENGN. Altitude Crest Partners Inc. acquired a new stake in shares of enGene in the 1st quarter valued at approximately $2,039,000. Janus Henderson Group PLC acquired a new stake in shares of enGene in the first quarter valued at about $17,095,000. Omega Fund Management LLC purchased a new stake in enGene during the fourth quarter worth about $10,441,000. Finally, BVF Inc. IL purchased a new stake in enGene during the fourth quarter worth about $20,777,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Price Performance

enGene stock opened at $7.21 on Friday. The firm’s 50-day moving average is $7.30 and its two-hundred day moving average is $11.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 42.80. The stock has a market capitalization of $318.44 million, a P/E ratio of -4.34 and a beta of -0.67. enGene Holdings Inc. has a 12-month low of $4.94 and a 12-month high of $43.00.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. Equities analysts predict that enGene Holdings Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Oppenheimer began coverage on enGene in a research note on Wednesday, August 28th. They issued an “outperform” rating and a $30.00 price objective for the company. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $33.67.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.